Drug Trial Radar · NCT00351468
EXTEND (Eltrombopag Extended Dosing Study)
Last checked: Nov 20, 2026Latest source record: Apr 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
302
Actual
Start
Jun 2006
Primary completion
Jul 2015
Study completion Jul 2015
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 12, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial. This study will allow adjustment of the eltrombopag dose to achieve an individualized dose and schedule for each subject. In addition, the ability to reduce the dose of concomitant ITP medications in the presence of eltrombopag, while maintaining platelet counts = 50,000/μL will be investigated.
Conditions
- Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag olamine (SB-497115-GR)Drug
Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Summary of On-Therapy Adverse Events (Safety Population)Time frame: Start date was the first dose of investigational product and up to the day after the last dose . Post-therapy: start date was more than 1 day after the last dose and up to 30 days after last dose of investigational product up to week 364
Locations
110 sites in 31 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Huntsville, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Jonesboro, Arkansas
Novartis Investigative Site
Duarte, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Savannah, Georgia
Novartis Investigative Site
Peoria, Illinois
Novartis Investigative Site
New Orleans, Louisiana
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Detroit, Michigan
Novartis Investigative Site
Brunsville, Minnesota
Novartis Investigative Site
Albuquerque, New Mexico
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Cleveland, Ohio
Novartis Investigative Site
Portland, Oregon
Novartis Investigative Site
Lubbock, Texas
Novartis Investigative Site
Arlington, Virginia
Novartis Investigative Site
Seattle, Washington
Novartis Investigative Site
Tacoma, Washington
Novartis Investigative Site
Vancouver, Washington
Novartis investigative Site
Garran, Australian Capital Territory, Australia
Novartis Investigative Site
Kogarah, New South Wales, Australia
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Hamilton, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Jiang Su Province, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Odense, Denmark
Novartis Investigative Site
Kuopio, Finland
Novartis Investigative Site
Caen, France
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Pessac, France
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.